Pharmaceuticals perspectives of high pressure : a soft tool for sterilization of fragile drugs

Yohan Rigaldie (1, 2, 3) , Gilles Lemagnen (3) , Alain Largeteau (1) , Denis Larrouture (3) , M. Abba (2, 3) , R. Haller (2) , Luc Grislain (3) , Gérard Demazeau (1)

1 ICMCB - Institut de Chimie de la Matière Condensée de Bordeaux
2 Ellipse Pharmaceutical
3 LTIP - Laboratoire de Technologie Pharmaceutique Industrielle

In this study, we showed the safety of HHP (High Hydrostatic Pressure) treatment on several fragile biomolecules (molecular weight from 1200 up to 150 000 g/mol : two peptides, insulin, antibodies). A HHP treatment (10 min at 400 MPa) inactivates totally pure suspensions of P. aeruginosa and C. albicans. HHP at low temperature induces a stronger inactivation than at room temperature. S. aureus needs a longer HHP duration treatment or a multi-step treatment to be totally inactivated. But same tests applied to B. subtilis did not lead to a total inactivation; further processes are in progress in order to cause spores of B. subtilis to germinate

Mots clés: High pressure; Drugs; Sterilization

Domaines: Sciences pharmaceutiques; Génie des procédés

Yohan Rigaldie, Gilles Lemagnen, Alain Largeteau, Denis Larrouture, M. Abba, et al.. Pharmaceuticals perspectives of high pressure : a soft tool for sterilization of fragile drugs. Defect and Diffusion Forum, 2002, 208-209, pp.55-58. ⟨10.4028/www.scientific.net/DDF.208-209.55⟩. ⟨hal-00715310⟩